All data are based on the daily closing price as of December 24, 2024
e

EirGenix

6589.TWO
2.17 USD
-0.02
-0.91%

Overview

Last close
2.17 usd
Market cap
663.95M usd
52 week high
3.44 usd
52 week low
2.09 usd
Target price
3.52 usd

Valuation

P/E
N/A
Forward P/E
N/A
Price/Sales
19.1454
Price/Book Value
2.3256
Enterprise Value
541.63M usd
EV/Revenue
15.1265
EV/EBITDA
-32.1413

Key financials

Revenue TTM
34.68M usd
Gross Profit TTM
23.13M usd
EBITDA TTM
-24.12M usd
Earnings per Share
-0.1 usd
Dividend
N/A usd
Total assets
10.93B usd
Net debt
-3.52B usd

About

EirGenix Inc. operates as a contract development and manufacturing company in Taiwan and internationally. The company offers cell line development, process development, analytical and quality control, cGMP manufacturing mammalian and microbial system, and antibody-drug conjugate services. It is also involved in the development of EG12014/EGI014, a Trastuzumab biosimilar, indicated for the treatment of cancer and currently under biologics license application status; EG1206A, a Pertuzumab biosimilar, indicated for the treatment of cancer and currently under Phase I stage; EG13074, indicated for the treatment of cancer and currently under Preclinical stage; TSY0110(EG12043), an antibody-drug conjugate, indicated for the treatment of cancer and currently under Preclinical stage; EG12021, Bevacizumab biosimilar, indicated for the treatment of cancer and currently under Preclinical stage; and EG62054, a biosimilar, currently under Preclinical stage. In addition, the company manufactures and sells covid-19 antigen rapid test; and EG74032, a CRM197 carrier protein. The company was incorporated in 2012 and is headquartered in New Taipei City, Taiwan.
  • Symbol
    6589.TWO
  • Exchange
    TWO
  • Isin
    TW0006589005
  • Country
    Taiwan
  • Sector
    Healthcare
  • Industry
    Biotechnology
  • CEO
    Dr. Lee-Cheng Liu
  • Headquarter
    New Taipei City
  • Web site
    https://www.eirgenix.com
Jakota Newsletter

Stay ahead in the JAKOTA stock markets with our roundup of vital insights

Icon scroll to top